| 3.66 -0.16 (-4.19%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.47 |
1-year : | 4.82 |
| Resists | First : | 3.82 |
Second : | 4.13 |
| Pivot price | 3.64 |
|||
| Supports | First : | 3.32 |
Second : | 2.77 |
| MAs | MA(5) : | 3.75  |
MA(20) : | 3.69 |
| MA(100) : | 3.96 |
MA(250) : | 5.01 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 61 |
D(3) : | 67.5 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 8.1 | Low : | 3.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BCYC ] has closed below upper band by 47.0%. Bollinger Bands are 16.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.8 - 3.82 | 3.82 - 3.84 |
| Low: | 3.56 - 3.58 | 3.58 - 3.6 |
| Close: | 3.62 - 3.66 | 3.66 - 3.69 |
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.
Fri, 30 Oct 2026
Bicycle Therapeutics Reports Q3 2026 Revenue of $34.1 Million, M - GuruFocus
Thu, 29 Oct 2026
Jefferies cuts Bicycle Therapeutics stock price target on trial timing By Investing.com - Investing.com UK
Thu, 29 Oct 2026
Q3 revenue rises on Bayer’s exit at Bicycle Therapeutics (BCYC). - Stock Titan
Thu, 29 Oct 2026
Bicycle Therapeutics plc (BCYC) Tops Q3 EPS by 25c - StreetInsider
Thu, 29 Oct 2026
Bicycle Therapeutics Reports Q3 2026 Results, $469.9 Million in Cash - TradingView
Thu, 29 Oct 2026
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 7.76e+006 (%) |
| Held by Institutions | 4.5 (%) |
| Shares Short | 3,280 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.0081e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 673.9 % |
| Return on Equity (ttm) | -18 % |
| Qtrly Rev. Growth | 6.12e+007 % |
| Gross Profit (p.s.) | -46.73 |
| Sales Per Share | -19.23 |
| EBITDA (p.s.) | -7.61012e+007 |
| Qtrly Earnings Growth | -2.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -206 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.2 |
| Price to Cash Flow | 0.84 |
| Dividend | 0 |
| Forward Dividend | 3.3e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|